1,229
Views
4
CrossRef citations to date
0
Altmetric
Oncology

Healthcare utilization and costs among relapsed or refractory multiple myeloma patients on carfilzomib or pomalidomide as monotherapy or in combination with dexamethasone

, , &
Pages 818-829 | Received 16 Jan 2019, Accepted 30 Apr 2019, Published online: 17 May 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Tilman Hans Steinmetz, Moushmi Singh, Andrea Lebioda, Leah Fink, Martina Schoehl, Achim Rieth, Sebastian Gonzalez-McQuire & Monika Engelhardt. (2021) Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany. Journal of Medical Economics 24:1, pages 114-122.
Read now

Articles from other publishers (3)

Enrique M. Ocio, Carmen Montes-Gaisán, Gabriela Bustamante, Sebastián Garzón, Esther González, Ernesto Pérez-Persona, Verónica González-Calle, Maialen Sirvent, José M. Arguiñano, Yolanda González, Rafael Ríos, Dunia de Miguel, Marta Grande, Alonso Fernández-Nistal, Andrea Naves & Laura Rosiñol. (2023) Real-World Health Care Services Utilization Associated With the Management of Patients With Relapsed and Refractory Multiple Myeloma in Spain: The CharisMMa Study. Clinical Lymphoma Myeloma and Leukemia.
Crossref
Christine Bennink, Marjolein van der Klift, Pieter Sonneveld, Jan A. Hazelzet & Hedwig M. Blommestein. (2022) High hospital-related burden of treatment for multiple myeloma patients: outcomes of a feasibility study using reimbursement data from electronic health records. Health Policy and Technology 11:4, pages 100695.
Crossref
Ankur A. Dashputre, Katie S. Gatwood & Justin Gatwood. (2020) Medication Adherence, Health Care Utilization, and Costs Among Patients Initiating Oral Oncolytics for Multiple Myeloma or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Journal of Managed Care & Specialty Pharmacy 26:2, pages 186-196.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.